Albumin, fatty-acid chains, and the engineering that made a weekly incretin possible
The molecular engineering that turned a peptide with a two-minute half-life into a once-weekly drug.
The archive
Page 167 of 170 of this archive, newest first.
Target dose, effective dose, and the distance between them
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
Retest date, expiry date, and the two conventions being confused
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 17 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
GGPeps declines, for the 3rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Deamidation, oxidation, and the two shifts worth memorising
What would be needed to catch each of these, and what it would cost.
Calder Vale Peptides of Skipton closes after 14 years
A proper account of an operation that existed, and of what closing it cost.
The 31-day notice: how a compounding wind-down works in Norway
The document is four pages. Three of them are about dates.
What changed at MKM in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Japan caps liraglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The badge economy, and what it is actually certifying
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
Lipohypertrophy, and the absorption it ruins
A rotation scheme that is too complicated will not be followed. We describe the simple ones that are.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The relabeller trading as Vantris Bio closes after 12 years
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a FGP liraglutide lot at 95.7%, against 95.0% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A percentage is not a specification
Chromatographic purity is cheap, fast and comparable-looking. Those three properties, and not its usefulness, explain why it became the industry’s single figure of merit.
What has to change before a change has happened
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Argentina caps exenatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What a 38% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
What the older diet-and-exercise trials found in the hip
A plausible mechanism, a measurable change, and no outcome data. This is what an open question looks like.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Denmark health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
The United Kingdom declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to Canada after 9 consecutive customs detentions
The route did not close because of a rule about peptides.
What “LC-MS: conforms” tells a reader, which is almost nothing
A short audit procedure, usable by anyone holding a certificate and a calculator.
Stepping down is part of titration
The practice is near-universal, clinically sensible, and supported by observational data rather than randomised comparison. We say which is which.